Kornimate/medical-research-clean huggingface dataset:
stress urinary incontinence and sarcopenia in postmenopausal osteoporosis

Conditions: Osteoporosis, Postmenopausal

Summary: the primary aim of our study is to evaluate the presence of stress urinary incontinence in postmenopausal patients with and without osteoporosis, determine its impact on quality of life, and explore its relationship with sarcopenia.

one hundred postmenopausal women, aged 50-75, who applied to the physical therapy and rehabilitation outpatient clinic at beylikdüzü state hospital and have dual-x-ray absorptiometry (dxa) measurements taken within the last 6 months, including both osteoporotic and non-osteoporotic patients, will be included in the study. sociodemographic data such as age, gender, height, weight, and bmi will be recorded. dxa results, including femoral neck and l1-l4 t-scores and bmd values, will be obtained. patients will be asked about osteoporosis treatment, presence of fecal incontinence, constipation, and medication use. stress urinary incontinence will be determined through a questionnaire, and its impact on quality of life will be assessed using the incontinence quality of life scale. in the second phase, sarcopenia will be evaluated according to the asian working group for sarcopenia (awgs) criteria by assessing skeletal muscle mass (via bioelectrical impedance analysis), handgrip strength, and the 5-times sit-to-stand test.

Eligibility criteria:
inclusion criteria: * postmenopausal women with dxa measurements performed within the last 6 months. * based on dxa measurements: femoral neck and l1-l4 t-scores of -1 and above will be included in the control group (non-osteoporotic). femoral neck and l1-l4 t-scores of -2.5 and below will be included in the osteoporosis group. * aged 50-75 years exclusion criteria: * refusal to participate in the study. * history of neurological diseases, infections, surgeries, or trauma that could cause urinary incontinence or muscle loss. * presence of psychiatric disorders. * cognitive impairments. * use of medications that could affect the study results.
the management of postoperative craniotomy pain in pediatric patients

Conditions: Post Craniotomy Surgery; Cancer; Epilepsy; Vascular Malformations; Craniofacial Reconstructive Surgery

Summary: the purpose of this prospective, clinical observational trial is to assess the incidence of pain (and analgesia), methods of pain assessment (and by whom), prescribed analgesics, methods of analgesic delivery, and patient/parent satisfaction in patients undergoing craniotomy surgery at three major children's hospitals (boston children's hospital, children's hospital of philadelphia, the children's center johns hopkins hospital) in the united states.


Eligibility criteria:
inclusion criteria: * pediatric patients 0-18 years, who are scheduled to undergo craniotomy surgery for any reason (e.g., brain tumor, epilepsy surgery, craniofacial reconstruction) at either the boston children's hospital, the children's hospital of philadelphia, or the children's center of the johns hopkins hospital will be eligible for enrollment. exclusion criteria: * patients who remain intubated after surgery. additionally, we will exclude patients who are allergic to opioids or who have a history of substance abuse

Keywords: pediatrics acute pain neurosurgery pediatric patients (0-18) postoperative management
home-based cognitive monitoring in mci

Conditions: Mild Cognitive Impairment

Summary: this study is an observational study to confirm usefulness of a home-based cognitive monitoring in non-demented patients with high-risk of dementia

we prospectively enroll subjects who were diagnosed as mild cognitive impairment based on neuropsychological tests battery, brain mri, and routine blood labs including thyroid function tests, vitamine b12 \& folate levels, and syphilis screening to rule out other secondary causes of dementia. we undergo peripheral blood-based amyloid beta levels and regular home-based cognitive monitoring (every 3 months) to investigate whether amyloid-positive mcis progress rapidly using home-based cognitive monitoring during 6 months.

Eligibility criteria:
inclusion criteria: * persistent cognitive complaints * aged 50 years old or older * below -1.0 standard deviation in any domain of detailed neuropsychological tests battery named snsb (seoul neuropsychological screening battery) * no adl (activities of daily living) limitation * subjects who agreed to participate exclusion criteria: * dementia patients * other structural brain disorders such as hydrocephalus, hemorrhage, or tumors * other neurological disease such as huntington's disease, parkinson's disease, or epilepsy

Keywords: mild cognitive impairment blood amyloid beta home-based cognitive monitoring
study of alvimopan for the management of opioid-induced postoperative bowel dysfunction/postoperative ileus

Conditions: Ileus

Summary: patients undergoing major abdominal surgery are at highest risk for developing postoperative ileus (poi), occurring in nearly all cases. signs and symptoms of poi may include abdominal distention, bloating, persistent abdominal pain; nausea and/or vomiting; delayed passage or inability to pass flatus or stool; and inability to tolerate a solid diet. this study will test the ability of alvimopan 6 mg or 12 mg given 2 hours before the scheduled start of surgery to hasten the recovery of gi function in patients undergoing major abdominal surgery (bowel resection or abdominal hysterectomy).

postoperative ileus (poi) is temporary slowing down or stopping of bowel function and a slowing down of movement of contents of the intestines. this functional impairment persists for a variable duration following surgery, usually resolving within 1 day in the small intestine, 1 to 3 days in the stomach and 3 to 5 days in the colon. when poi persists for more than 5 days, it is generally considered severe, sometimes referred to as complicated or prolonged poi, and increases the risk for related morbidity. no drug therapy has been shown to consistently shorten the duration of poi. this study is designed to demonstrate that alvimopan, a novel, peripherally acting mu opioid receptor antagonist, accelerates the recovery of gi function in patients undergoing bowel resection of hysterectomy.

Eligibility criteria:
inclusion criteria: * subject is scheduled for a partial small/large bowel resection of primary anastomosis or total abdominal hysterectomy (simple or radical) via laparotomy * subject is scheduled to receive primary postoperative pain management with intravenous (i.v.) patient-controlled analgesia (pca) opioids exclusion criteria: * subject is scheduled for a total colectomy, colostomy, ileostomy * subject has complete bowel obstruction * subject is currently taking opioid analgesics or has taken opioid analgesics within the prior 2 weeks

Keywords: postoperative ileus
study of comprehensive and multimodal marker-based cohort of progressive supranuclear palsy(psp)

Conditions: Progressive Supranuclear Palsy

Summary: the purpose of this cohort study is to develop a reliable biomarker in progressive nuclear palsy (psp).

progressive supranuclear palsy is a rapidly progressive neurodegenerative disease without a cure. thus, the development of a biomarker that reflects and monitors disease severity in psp is critical for early diagnosis and performing a successful clinical trial. thus, we will prospectively recruit patients with psp and collect comprehensive clinical, imaging and blood biomarkers at baseline with longitudinal follow-up for 1 year.

Eligibility criteria:
inclusion criteria for the patient group: * age 50 to 80 years, male or female * progressive supranuclear palsy (psp) patients who are diagnosed as probable, possible or suggestive psp with movement disorder society diagnostic criteria for psp (hoglinger et al., 2017) exclusion criteria for the patient group: * subjects with clinically significant psychiatric illness * subjects with cancer or severe medical illness * lactating, pregnant, or possibly pregnant * subjects with small vessel disease (\> grade ii) in brain mri or other structural lesions by causes other than psp * subjects with severe dementia patients (mmse \ = 5) inclusion criteria for the healthy control group: * age 50 to 80 years, male or female * those who agreed to participate in this study exclusion criteria for the healthy control group: * those with a history of any neurological diseases * lactating, pregnant, or possibly pregnant * subjects with clinically significant psychiatric illness * subjects with cancer or severe medical illness
the effect of uterine entry in fetoscopic laser photocoagulation for twin-to-twin transfusion syndrome

Conditions: Twin to Twin Transfusion

Summary: the purpose of this study is to evaluate whether the entry technique surgeons use to get inside the uterus to perform fetoscopic laser photocoagulation for twin-to-twin transfusion syndrome has an effect on the rates of chorioamniotic membrane separation.

patients who choose to undergo fetoscopic selective laser photocoagulation (sflp) at texas children's fetal center will be offered participation in this research study by study investigators. description of study rationale and design and a focused interview by the study coordinator to afford potential participants a formal opportunity to examine what they have learned about the research study in the course of their evaluation and discuss how they feel about enrolling in the research study. once the patient is deemed eligible the informed consent process will be reviewed. if patients elect to participate in the study, informed consent will be obtained, and participants will be provided a copy of the signed consent. after consent has been obtained, participants will be randomized into two groups ("direct entry" and "seldinger technique"). procedure: selective laser photocoagulation (sflp) is standard of care for the treatment of complicated monochorionic twin pregnancies. entry into the uterus for sflp is achieved under ultrasound guidance using one of two accepted methods, direct entry or the seldinger technique. intravenous sedation with local anesthesia at the site of insertion has been found to provide sufficient maternal anesthesia for the procedure. group i - direct entry: the surgeon will gain access to the uterus by inserting a sharp trocar through a small incision in the skin. after access has been established, the trocar is removed and a small tube called a cannula is left in place. group ii - seldinger technique: the surgeon will gain access to the uterus by inserting needle through a small incision in the skin and run a guide wire through the needle so a thin tube called a cannula can be placed over the wire. follow-up: participants will be monitored after the procedure and upon discharge from the hospital they are free to resume care with their primary doctor. investigators will collect follow-up data on the health of the participant and the babies until the babies turn one month old.

Eligibility criteria:
inclusion criteria: * patients who are eligible and elect to undergo fetoscopic selective laser photocoagulation for complicated monochorionic-diamniotic twin pregnancies with twin-to-twin transfusion syndrome. exclusion criteria: * patients who do not elect to undergo fetoscopic laser photocoagulation for the treatment of complicated monochorionic-diamniotic twin pregnancies with twin-to-twin transfusion syndrome. * triplets and higher order multiple gestations.

Keywords: fetoscopic laser photocoagulation ttts uterine entry direct entry seldinger technique chorioamniotic membrane separation cas
transverse colostomy for refractory hemorrhagic chronic radiation proctitis: a prospective cohort study

Conditions: Chronic Radiation Proctitis; Rectal Bleeding; Colostomy Stoma; Anemia

Summary: refractory rectal bleeding of chronic radiation proctitis (crp) is still problematic and does not respond to medical treatments including reagents, endoscopic argon plasma coagulation (apc) or topical formalin. we proposed this prospective cohort study, to assess the efficacy and safety of colostomy in treating refractory hemorrhagic crp with moderate to severe anemia, to provide higher-quality evidence of colostomy in these patients.

chronic radiation proctitis (crp) is a common complication after radiotherapy of pelvic malignancies, accounting for 5%-20% of cases. rectal bleeding is the most common symptom, which accounts for \> 80% of crp patients. mild to moderate bleeding can be controlled by medical agents like sucralfate, endoscopic argon plasma coagulation (apc) or topical formalin. severe and refractory bleeding is still problematic and refractory to these above medical treatments. our previous retrospective study found that colostomy obtained a higher rate of bleeding remission (94% vs 12%) in 6 months, especially in control of transfusion-dependent bleeding (100% vs0%), when compared to conservative treatments.

Eligibility criteria:
inclusion criteria: * histologically diagnosed with pelvic malignancies, including gynecologic, prostate, or urinary cancers; * history of pelvic radiation; * no tumor recurrence or metastasis; * refractory hemorrhagic crp; * time of rectal bleeding \>6 months; * sobs=3 points; * severe anemia （hb≤7 g/dl）or transfusion history for crp bleedings. exclusion criteria: * severe complications of crp, including deep ulcer or fistula, stricture, necrosis, refractory perianal pain; * other hemorrhagic diseases, like iii-iv degree hemorrhoids; * history of colon or rectum resection; * intestinal obstruction and surgery needed; * with contraindications to general anaesthesia (asa class 4 or 5); * pregnant or breast-feeding; * history of mental disorder.

Keywords: chronic radiation proctitis rectal bleeding transverse colostomy refractory moderate to severe anemia
study of oral md-0727 administered to patients with primary hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the primary objectives of this study are to evaluate the safety of md-0727 in patients with primary hypercholesterolemia and to determine the low density lipoprotein cholesterol (ldl-c) lowering effect and dose-response of md-0727 in patients with primary hypercholesterolemia.


Eligibility criteria:
inclusion criteria: * patient is male or non-pregnant, non-breastfeeding female, at least 18 years of age * patient must agree to use contraception and/or birth control if sexually active * patient may not be on lipid-lowering therapies at least 6 weeks prior to study and must have a fasting ldl-c 130 mg/dl or greater at screening * patient must have an average of two fasting ldl-c measures greater than/equal to 130 mg/dl but less than/equal to 210 mg/dl with a difference in the two measures less than/equal to 15%. patient may not have a fasting serum triglyceride less than 300 mg/dl during pre-treatment period * patient's bmi must be greater than/equal to 18.5 but less than 35.0 at screening * patient must complete a physical exam, 12-lead ecg, and other laboratory tests (including pregnancy test) with no clinically-significant findings prior to the first dose of study medication * patient agrees to comply with the tlc diet * patient completes a 6-week washout of previous lipid-lowering medication including over-the-counter products exclusion criteria: * patient has a medical condition that is prohibited per protocol or a condition that the investigator believes may limit the patient's ability to participate in the study * patient has a tsh level \>1.5 x the upper limit of normal * patient has history of cardiovascular or coronary artery disease, uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins, or patient has history of nyha class iii or iv congestive heart failure * patient is diabetic or presents with fasting blood glucose greater than/equal to 126 mg/dl at any time prior to randomization * patient has uncontrolled hypertension with a systolic blood pressure greater than/equal to 180 mm hg or diastolic blood pressure greater than/equal to 110 mmg hg at two study visits prior to the first dose of study medication * patient has a 10-year chd risk of \> 20% * patient has alt or ast \> 1.5 x the upper limit of normal prior to randomization * patient has a history of alcohol or drug abuse within 12 months of screening * patient has used a prohibited medication (per protocol) during the 14-day pre-treatment visit

Keywords: microbia md-0727 primary hypercholesterolemia hypercholesterolemia hyperlipidemia dyslipidemia cholesterol ldl
effect of pilates exercises on diastasis recti abdominis in postpartum women

Conditions: Diastasis Recti

Summary: the purpose of the study was to investigate the effect of pilates exercises on diastasis recti abdominis in postpartum women.

rectus diastasis is relatively common having negative health consequences for women during and after pregnancy (ante-and postnatal periods). varying estimates of incidence of rectus diastasis have been reported ranging from 66% to 100% during the third trimester of pregnancy, and up to 53% immediately after delivery. among patients with urogynecological disorders, 52% were found to have a rectus diastasis and 66% had at least one type of pelvic floor dysfunction. a diastasis can contribute to lower back pain and strain due to other muscles being overworked or compensating for the lack of integrity of abdominals, unstable core, pelvic and back muscles, poor posture, shallow breathing and uterine prolapse. this may result in altered trunk mechanics, impaired pelvic stability and changed posture, which leave the lumbar spine and pelvis more vulnerable to injury. facilitation, concentric activation, and stabilization of the abdominal muscles occurred during core stability exercise are used to correct diastasis recti. pilates has been known to improve the strength and flexibility of muscles, particularly the abdominal muscles, lower back, hip and buttocks i.e. the core musculature thus helping in improving core stability. uptill now, there was no previous studies have examined the impact of pilates training on rectus abdominis diastasis in postpartum women. so, this study will be valuable benefits for medical services organizations and will increase body of knowledge of physical therapists in scientific field.

Eligibility criteria:
inclusion criteria: 1. postpartum women (7 days after delivery) having diastasis recti (separation between the two recti more than 2.5cm at the level of umbilicus). 2. multiparous women (2-3) times delivered vaginally with or without episiotomy. 3. their age ranged from 20 -35 years old. 4. their bmi was less than 30 kg/cm2. exclusion criteria: 1. abdominal or back surgery. 2. abdominal hernia. 3. history of abnormal pregnancy, uterine fibroid or polyhydraminos during pregnancy. 4. neurological disorders as multiple sclerosis, stroke and spinal lesion. 5. musculoskeletal diseases such as fractures muscle strains, severe knee osteoarthritis which may affect their physical activity.

Keywords: pilates exercises diastasis recti abdominis postpartum women
fibromyalgia health outcome study on cost of treatments

Conditions: Fibromyalgia

Summary: the real world examination of fibromyalgia: longitudinal evaluation of costs and treatments (reflections) study is a 12-month, prospective observational study that will be utilized in approximately 58 care settings in the united states (us) and puerto rico. it is designed to examine treatment patterns and health outcomes of adult participants diagnosed by their physician with fibromyalgia (fm) and who are starting any "new pharmacologic agent" for fm. the primary benefit of this study is enhanced understanding of the disease state of fm and the role that pharmacologic treatment plays, which may help to optimize management of fm. this study will address current gaps in a rapidly growing body of literature on fm.


Eligibility criteria:
inclusion criteria: * meet criteria for fibromyalgia (fm) in the opinion of the investigator * must be prescribed a 'new' treatment for fm * male and female participants at least 18 years of age * willing to complete the informed consent document (icd) and any other required forms to be eligible for study participation * currently under the care of the participating physician * cognitively able to understand and complete participant self-rated scales in english or spanish via computer-assisted telephone interview (cati) * available for 12 months to participate in the study exclusion criteria: * are investigator site personnel directly affiliated with the study and/or their immediate families. immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted * are lilly employees * are terminally ill * currently participating in other research studies or if beginning a research study while participating in this study * unable to respond via telephone for cati * incompetent for interview as deemed by the participating physician * unwilling to provide written icd or other required forms to participate in the study
optimisation of asthma in those with uncontrolled symptoms (oasis)

Conditions: Asthma; Asthma Attack; Asthma Persistent; Covid19

Summary: a digital tool, called referid has been developed to facilitate the review of asthma patients. it aims to assist in the identification of patients with uncontrolled and/or severe asthma and to ensure a timely referral to secondary care where appropriate. to validate the tool, patients will be randomised to have a review with a healthcare professional using tool to facilitate the review or to continue receiving usual care. outcome measures including exacerbation frequency and level of asthma control will be assessed at 12 months.


Eligibility criteria:
inclusion criteria: * all asthma patients with 1 of more exacerbations in the last 12 months or receiving high dose inhaled corticosteroids. * patients able and willing to provide informed consent. * patients aged 18 and over. exclusion criteria: * patients who lack capacity. * patients who do not have a diagnosis of asthma * patients who are unable to provide informed consent * patients under the age of 18 * patients already under a severe asthma centre
safety and effectiveness of giving indinavir plus stavudine plus lamivudine to hiv-infected children

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give an anti-hiv drug combination of indinavir (idv) plus stavudine (d4t) plus lamivudine (3tc) to hiv-infected children. idv will be given either as a powder mixed into applesauce or as capsules given on an empty stomach.

in this multicenter, open-label study patients receive a combined drug regimen of indinavir, stavudine, and lamivudine over 48 weeks. patients are evaluated at weeks 0, 2, 4, every 4 weeks until week 24, and every 8 weeks thereafter until study completion. \[as per amendment 4/27/99: the study has been extended for an additional 48 weeks for a total of 96 weeks.\]

Eligibility criteria:
inclusion criteria your child may be eligible for this study if he/she: * is 3 - 15 years old and has consent of a parent or legal guardian who is able to return with the child for follow-up visits. * is hiv-positive. * is generally healthy. * is able to swallow medication in capsule form. * has never taken d4t or has never taken 3tc. * agrees to use barrier methods of birth control (such as condoms) during the study. the pill is not allowed during the study. exclusion criteria your child will not be eligible for this study if he/she: * has a serious infection at the time of study entry. * has a history of severe diarrhea. * is unable to take any of the medications in this study for any reason. * has a history of certain serious illnesses. * has taken any protease inhibitors (pis). * has taken any non-nucleoside reverse transcriptase inhibitors (nnrtis), such as efavirenz (efv), within 2 weeks prior to study entry. * has taken certain medications. * is pregnant or breast-feeding.

Keywords: dose-response relationship, drug drug therapy, combination stavudine hiv protease inhibitors lamivudine indinavir rna, viral reverse transcriptase inhibitors viral load